A BILL 
To amend the Internal Revenue Code of 1986 to restore 
the amount of the orphan drug tax credit, and for other 
purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as ‘‘Cameron’s Law’’. 
4
04:06 Mar 26, 2020
H6238
2 
•HR 6238 IH
SEC. 2. RESTORATION OF AMOUNT OF ORPHAN DRUG TAX 
1
CREDIT. 
2
(a) IN GENERAL.—Section 45C(a) of the Internal 
3
Revenue Code of 1986 is amended by striking ‘‘25 per-
4
cent’’ and inserting ‘‘50 percent’’. 
5
(b) EFFECTIVE DATE.—The amendment made by 
6
this section shall apply to taxable years beginning after 
7
the date of the enactment of this Act. 
8
SEC. 3. CDC STUDY ON SURVEILLANCE INFRASTRUCTURE 
9
FOR RARE DISEASES AND CONDITIONS. 
10
(a) STUDY.—Not later than 1 year after the date of 
11
enactment of this Act, the Director of the Centers for Dis-
12
ease Control and Prevention (in this section referred to 
13
as the ‘‘Director’’) shall complete a study on enhancing 
14
and expanding the infrastructure to track the epidemi-
15
ology of rare diseases and conditions, including with re-
16
spect to the following: 
17
(1) Rates of mortality. 
18
(2) Potential for research and treatment. 
19
(3) Demographics. 
20
(4) Diagnosis and progression markers. 
21
(5) The history of the disease or condition. 
22
(6) Detection management. 
23
(b) CONSULTATION.—In conducting the study re-
24
quired by subsection (a), the Director shall consult with 
25
relevant experts, including— 
26
04:06 Mar 26, 2020
H6238
3 
•HR 6238 IH
(1) epidemiologists with experience in disease 
1
surveillance; 
2
(2) representatives of national voluntary health 
3
associations; 
4
(3) health information technology experts or 
5
other information management specialists; 
6
(4) clinicians with expertise in rare diseases or 
7
conditions; 
8
(5) research scientists with expertise in rare 
9
diseases or conditions, or experience conducting 
10
translational research or utilizing surveillance sys-
11
tems for scientific research purposes; and 
12
(6) patients, and caregivers of patients, with 
13
rare diseases or conditions. 
14
(c) REPORT.—Not later than 3 months after com-
15
pleting the study required by subsection (a), the Director 
16
shall submit a report to the Congress on the results of 
17
the study. 
18
(d) DEFINITION.—In this section, the terms ‘‘rare 
19
diseases and conditions’’ and ‘‘rare diseases or conditions’’ 
20
refer to human diseases and conditions that are— 
21
(1) a rare disease or condition, as defined in 
22
section 526 of the Federal Food, Drug, and Cos-
23
metic Act (21 U.S.C. 360bb); or 
24
04:06 Mar 26, 2020
H6238
4 
•HR 6238 IH
(2) determined by the Director to be rare and 
1
lacking in treatment options, so as to warrant con-
2
sideration in the study required by subsection (a). 
3
Æ 
04:06 Mar 26, 2020
H6238
